Antimicrobial Use Guidelines (AMUG) version 21 - UW Health

More documents

Recommendations

Info

47. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relativebioavailability of two oral formulations of posaconazole in healthy adults. Br J ClinPharmacol 2003;57:218-222.48. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantalo SR, GreinixH, de Azvedo WM, Reddy V, Bopari N, Pedicone L, Patino H, Durrant S. Posaconazoleor fluconazole for prophylaxis in severe graft-versus-host disease. New Engl J Med2007;356:335-347.49. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D,Holowiecki J, Stockelberg D, Goh Y-T, Petrini M, Hardalo C, Suresh R, Angulo-GonzalezD. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients withneutropenia. New Engl J Med 2007;356:348-359.50. Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, Wingard JR.Prevention and early treatment of invasive fungal infection in patients with cancer andneutropenia and in stem cell transplant recipients in the era of newer broad-spectrumantifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402-409.51. Chapman SW, Bradsher RW, Campbell DG, Pappas PG, Kauffman CA. Practiceguidelines for the management of patients with blastomycosis..Clin Infect Dis 2008;46:1801-1252. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE.Guidelines for the treatment of candidiasis. Clin Infect Dis 2009;48:503-3553. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Haymill RJ, Harrison TS,Larsen RA, Lortholary O, Nguyen M-H, Pappas PG, Powderly WG, Singh N, Sobel JD,Sorrell TC. Clinical Practice Guidelines for the management of cryptococcal disease:2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291-322.54. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazoleversus voriconazole for prevention of invasive fungal infection after allogeneneichematopoietic cell transplantation. Blood 2010;116(24):5111-5118.
Appendix F: UWHC Guideline for Medication Route Interchange in Adult PatientsGuideline developed by UWHC Center for Drug PolicyCoordination: Lee Vermeulen, MS, RPh, FCCP, Director, Center for Drug PolicyLast Revised by: Wendy Horton, PharmD, BCPS; Kerry Goldrosen, PharmDApproved by P&T: June 2009Next Scheduled Review Date: June 2011A. BackgroundThis guideline outlines the framework and clinical criteria to support the UWHC MedicationRoute Interchange Protocol.B. CriteriaTo initiate interchanges in the route of medication administration (from parenteral to enteralroute, including administration via various feeding tubes), the pharmacist will assess forappropriateness based on the following criteria:1.0 Parenteral to EnteralTo initiate the parenteral to enteral interchange, which includes medications administeredorally or via feeding tubes, the medication must be listed in Table 1. In addition, patientsmust meet all inclusion criteria and none of the exclusion criteria.1.1 Inclusion Criteria1.1.1 Patient must have a diet order and be tolerating either a clear liquid or moreadvanced diet or must be tolerating enteral tube feedings.1.1.2 Patient must have the ability to adequately absorb medications via theenteral route.1.2 Exclusion Criteria1.2.1 Patient is unable to swallow, is strict NPO, or refuses oral medications.1.2.2 Severe vomiting or diarrhea has been documented within the past 24 hoursor patient has an acute condition that affects gastrointestinal absorption (i.e.gastrointestinal obstruction or bleed, severe diarrhea, ileus, severe vomitingor mucositis).1.2.3 Patient is hemodynamically unstable (sustained heart rate >100beats/minute, respiratory rate >24 breaths/minute, systolic blood pressure100beats/minute, respiratory rate >24 breaths/minute, systolic blood pressure
Page 2 and 3:
PREFACEThe Antimicrobial Use Guidel
Page 4 and 5:
Antimicrobial Cost Table (Cost info
Page 6 and 7:
Summary of Antibiotic Order Form: S
Page 8:
LUNGS/PULMONARYCommunity-Acquired P
Page 12 and 13:
PART I: BY DRUGABACAVIRFor up-to-da
Page 14 and 15:
constructed systemic-pulmonary shun
Page 16 and 17:
AMPICILLIN/SULBACTAM (Unasyn ® )Us
Page 18 and 19:
ATOVAQUONE/PROGUANIL (Malarone ® )
Page 20 and 21:
CEFAZOLINUsual DoseAdult: Moderate/
Page 22 and 23:
CommentsDose adjustment required fo
Page 24 and 25:
1. Typhoid fever. (NOTE: Third-gene
Page 26 and 27:
-Dutasteride-Eltrombopag-Theophylli
Page 28 and 29:
CLINDAMYCINUsual DoseAdult: 600-900
Page 30 and 31:
DAPTOMYCINInfectious Disease approv
Page 32 and 33:
Concurrent administration with peni
Page 34 and 35:
• Cisapride (contraindicated) •
Page 36 and 37:
• Oral contraceptives/hormones -
Page 38 and 39:
Synergy in infective endocarditis a
Page 40 and 41:
• Colchicine • Indinavir • Ta
Page 42 and 43:
• Donepezil • Pioglitazone• D
Page 44 and 45: with linezolid should be considered
Page 46 and 47: 4. Life-threatening Gram-negative i
Page 48 and 49: MOXIFLOXACINLevofloxacin and moxifl
Page 50 and 51: Indications1. Uncomplicated cystiti
Page 52 and 53: CommentsDose adjustment required fo
Page 54 and 55: PIPERACILLIN/TAZOBACTAM (Zosyn ® )
Page 56 and 57: PRIMAQUINEUsual DoseAdult: Malaria
Page 58 and 59: RIFABUTINUsual DoseAdult (150 mg ca
Page 60 and 61: • Chloramphenicol • Leflunomide
Page 62 and 63: SULFISOXAZOLENo longer available as
Page 64 and 65: TICARCILLIN/CLAVULANATE (Timentin
Page 66 and 67: 2. Recurrent urinary tract infectio
Page 68 and 69: VANCOMYCINUsual DoseAdult: 1 g Q12H
Page 70 and 71: Careful monitoring of patients usin
Page 72 and 73: APPENDIX B: UWHC SURGICAL ANTIMICRO
Page 74 and 75: GI:Appendectomy 3Anaerobic organism
Page 76 and 77: VascularLIKELYPATHOGENS• ANTIMICR
Page 78 and 79: Cleanorthopedicprocedures(other)Sta
Page 80 and 81: APPENDIX C: THERAPY FOR TUBERCULOSI
Page 82 and 83: p-Aminosalicylic acid(PAS)Granules
Page 84 and 85: Appendix D: UNIVERSITY OF WISCONSIN
Page 86 and 87: Appendix E: UWHC Guidelines for the
Page 88 and 89: B. Antifungal Prophylaxis for BMT a
Page 90 and 91: D. Cost ComparisonDrugAmphotericin
Page 92 and 93: 17. Maertens J, Glasmacher A, Herbr
Page 96 and 97: 2.1.7 Patient is without placement
Page 98 and 99: Medications Approved for Parenteral
Page 100 and 101: APPENDIX G: Serum Drug Concentratio
Page 102 and 103: APPENDIX H: Guidelines for Monitori
Page 104 and 105: 1. Patients with large volumes of d
Page 106 and 107: 16. Tsuji B, Rybak MJ. The influenc
Page 108 and 109: APPENDIX I: Infectious Diseases App
Page 110 and 111: APPENDIX J: UWHC Guidelines For the
Page 112 and 113: with aztreonam and other beta-lacta
Page 114 and 115: D. Side Chains1.2.5. The prescriber
Page 116 and 117: 14. Pichichiro ME. Use of selected
Page 118 and 119: Appendix KUWHC Guidelines for Cost-
Page 120 and 121: sulfa and can be prescribed topatie
Page 122 and 123: superinfection: amoxicillin 1 g PO
Page 124 and 125: 17. Smucny J, Fahey T, Becker L, Gl
Page 126 and 127: Appendix M: Guidelines for the Prop
Page 128 and 129: D. CategorizationPatients should be
Page 130 and 131: Empiric coverage for Enterococcus i
Page 132 and 133: H. Necrotizing PancreatitisThe publ
Page 134 and 135: Bone or JointEndocarditis 4Streptoc
Page 136 and 137: Candidemia or candidiasis 11Non-neu
Page 138 and 139: 11. Pappas PG, Kauffman CA, Andes D
Page 140 and 141: piperacillin/tazobactam. There were
Page 142 and 143: D. Dose of Antibiotic1. Piperacilli
Page 144 and 145:
TNAVasopressinVoriconazoleMeropenem
Page 146 and 147:
pretreatment with an H1-histamine b
Page 148 and 149:
formal consult is not required, but
Page 150:
K. References1.0 Bliziotis IA, Ples
show all

Antimicrobial Use Guidelines (AMUG) version 21 - UW Health

Create successful ePaper yourself

Delete template?

Save as template?